Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

218
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
218
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

278
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
278
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

387
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
387
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
169
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

188
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
188
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

241
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
241

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of very early and early enteral nutrition on intestinal permeability in children with pancreatitis: A randomized controlled study.

Anales de pediatria·2026
Same author

The impact of a pneumococcal vaccination on disease activity in children and adolescents with inflammatory bowel disease: a 2-year prospective study.

Expert review of vaccines·2026
Same author

Influence of body position on defecation mechanics measured during high-resolution anorectal manometry in paediatric population: a protocol for case-control study.

BMJ open·2025
Same author

From Polymorphisms to Phenotypes: <i>SMAD3</i> rs17293632 and <i>LTBP3</i> rs11545200 in Pediatric Inflammatory Bowel Disease.

Genes·2025
Same author

Validation of the Toronto Upper Gastrointestinal Cleaning Score in children.

Journal of pediatric gastroenterology and nutrition·2025
Same author

European Academy of Paediatrics demands protection of children's rights endangered by the ongoing Israel Gaza conflict.

Acta paediatrica (Oslo, Norway : 1992)·2024

Related Experiment Video

Updated: Aug 16, 2025

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

262

Old but Fancy: Curcumin in Ulcerative Colitis-Current Overview.

Aleksandra Pituch-Zdanowska1, Łukasz Dembiński1, Aleksandra Banaszkiewicz1

  • 1Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, 02-091 Warsaw, Poland.

Nutrients
|December 23, 2022
PubMed
Summary

Curcumin, a compound from turmeric, shows promise for ulcerative colitis (UC) therapy. Its anti-inflammatory properties may offer new treatment avenues for this chronic IBD.

Keywords:
anti-inflammatoryinflammatory bowel diseaseintestinal microbiotapolyphenols

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.4K
Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
06:39

Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis

Published on: October 27, 2023

1.0K

Related Experiment Videos

Last Updated: Aug 16, 2025

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

262
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.4K
Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
06:39

Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis

Published on: October 27, 2023

1.0K

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) affecting the colon and rectum.
  • Current UC treatments include mesalamine, steroids, immunosuppressants, and biologics, but management remains challenging.
  • There is an ongoing need for novel therapeutic strategies for UC.

Purpose of the Study:

  • To review the current scientific understanding of curcumin's role in ulcerative colitis therapy.
  • To explore the potential benefits of curcumin as an alternative or complementary treatment for UC.
  • To summarize curcumin's mechanisms of action relevant to IBD.

Main Methods:

  • Literature review of preclinical and clinical studies on curcumin and UC.
  • Analysis of curcumin's anti-inflammatory, antioxidative, and microbiota-modulating properties.
  • Synthesis of data on curcumin's impact on cellular pathways involved in IBD.

Main Results:

  • Curcumin exhibits significant anti-inflammatory, anticarcinogenic, and antioxidative effects.
  • Curcumin influences multiple cellular signaling pathways relevant to intestinal inflammation.
  • Evidence suggests curcumin impacts the gut microbiota composition and function.

Conclusions:

  • Curcumin presents a promising therapeutic agent for ulcerative colitis due to its multifaceted biological activities.
  • Further research and clinical trials are warranted to establish curcumin's efficacy and safety in UC management.
  • Curcumin may offer a novel approach to managing UC, potentially improving patient outcomes.